Lewis Freed, DPM
Podiatrist · Mesa, AZNPI 1407842941
Payments from drug & device makers
What this record shows
The money is spread across several categories — royalties or licence payments (59.0%), ownership interests and consulting fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Trice Medical, Inc. at 44.3% of the total. Reporting peaked in 2020 at $318,257 and has fallen 58.0% since, to $133,558 in 2025. Among podiatrist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $2575.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Trice Medical, Inc.$442K
- Paragon 28, Inc.$291K
- Tenex Health Inc.$173K
- Stryker$58K
- Arthrex$23K
- Musculoskeletal Transplant Foundation Inc.$5K
- plus $4K from 31 others
Across 22 payments — averaging $4042.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Globus Medical$47K
- Genentech, Inc.$17K
- Paragon 28, Inc.$12K
- Endo Pharmaceuticals Inc.$10K
- Bristol Myers Squibb$3K
What the payments were for
- Royalty or licence$587,94159%
- Consulting fees$113,02211%
- Speaking & faculty fees$10,6991%
- Travel & lodging$45,9465%
- Food & beverage$8,5481%
- Education$790%
- Gifts$1,3750%
- Ownership interest$229,16723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Trice Medical, Inc. | 77 | $442,006 |
| Paragon 28, Inc. | 54 | $290,901 |
| Tenex Health Inc. | 36 | $173,412 |
| Stryker(2 entities) | 86 | $58,235 |
| Arthrex | 39 | $23,096 |
| Musculoskeletal Transplant Foundation Inc. | 8 | $5,317 |
| Abbott | 7 | $1,156 |
| Impactortho, Inc. | 8 | $451 |
| Alafair Biosciences, Inc. | 1 | $183 |
| Orthofix Medical, Inc. | 18 | $165 |
| Averitas Pharma Inc. | 3 | $158 |
| Treace Medical Concepts, Inc. | 2 | $148 |
| Nalu Medical, Inc. | 1 | $145 |
| Boston Scientific | 3 | $135 |
| Kerecis Limited | 2 | $130 |
| Pacira Pharmaceuticals Incorporated | 1 | $122 |
| Bioventus LLC | 6 | $118 |
| Smith+Nephew | 5 | $116 |
| Exsomed Corporation | 1 | $104 |
| Biowound Solutions, Inc. | 8 | $100 |
| Merck | 1 | $97 |
| Acumed LLC | 2 | $88 |
| Osteomed LLC | 1 | $79 |
| Paratek Pharmaceuticals, Inc. | 4 | $64 |
| Carbofix Orthopedics Inc | 1 | $36 |
| Baxter Healthcare | 1 | $33 |
| Integra Lifesciences Corporation | 1 | $26 |
| Urgo Medical North America, LLC | 1 | $24 |
| Amgen | 1 | $21 |
| Surgenex LLC | 1 | $20 |
| Nevro Corp. | 1 | $18 |
| Lifenet Health | 1 | $18 |
| Mimedx Group, Inc. | 1 | $14 |
| Misonix Inc | 1 | $13 |
| Biocomposites Inc | 1 | $10 |
| Next Science LLC | 1 | $10 |
| Reprise Biomedical, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARTIVA$56,193
- Portfolio$29,470
- ARTHREX$28,373
- Product Portfolio$7,256
- DISTAL EXTREMITIES IMPLANTS FOREFOOT BUNION$6,917
- DISTAL EXTREMITIES IMPLANTS FOOT & ANKLE BUNION$1,666
- PROCLAIM$633
- INFINITY$598
- Kerecis SurgiClose$448
- AUGMENT$396
- Proclaim IPG$338
- Proclaim DRG IPG$184
- VersaWrap$183
- Nalu Neurostimulation System$145
- PROstep$136
- Qutenza$131
- Lapiplasty System$125
- EXPAREL$122
- MONKEY RINGS$118
- Kerecis GraftGuide$112
How this compares
$996,777 in reported general payments places this provider in the 95th percentile of 151 podiatrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 12 | $10,249 |
| Gabapentin | 386 | $5,876 |
| Doxycycline Hyclate | 69 | $767 |
| Pregabalin | 21 | $595 |
| Nortriptyline Hcl | 20 | $388 |
| Oxycodone Hcl | 64 | $313 |
| Duloxetine Hcl | 16 | $275 |
| SsdSilver Sulfadiazine | 14 | $177 |
| Meloxicam | 55 | $162 |
| Fluconazole | 20 | $149 |
| Celecoxib | 14 | $142 |
| Cephalexin | 14 | $110 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Mesa
- Kerry ZangMesa$111K
- Todd HaddonMesa$94K
- Spencer HardyMesa$4K
- Douglas GriffinMesa$2K
- Kimberly LeachMesa$1K
- Kris DinucciScottsdale$1.4M
- Stephen KominskySun City West$508K
- Chad WestphalPeoria$300K
- Paul BishopScottsdale$87K
- Barbara AungTucson$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.